A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Phase 0 Unknown 20 enrolled Zhejiang Cancer Hospital

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.

Timeline

Start: 2019-05-01
Primary completion: 2021-05-01
Completion: 2022-05-01

Publications

Shen D, Li R, She Y, Liu X, Huang Y, Ji Y, Chen K, Song Z, Chen R, Li X, Zhao Q, Chen Q, Chen M. PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma. Adv Sci (Weinh). 2026 Mar;13(17):e15207. doi: 10.1002/advs.202515207. Epub 2026 Jan 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sintilimab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Sintilimab	Monoclonal antibody	200 mg	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	50 mg/m2	Intravenous

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Summary

Timeline

Publications

Drugs

Indications